Oncology, Gerontology
Conditions
Brief summary
The increasingly used oral anticancer treatments allow the patient to reduce treatment and social constraints to reduce hospitalization costs. The counterpart is a decrease in the monitoring of the correct intake of drugs and the detection of side effects. These two risks are major in the elderly, due to comorbidities, poly-medication and decreased attention. The project objective to evaluate the impact of a bi-weekly nursing visit to the patients' homes for 3 months, compared to a conventional management without a nursing visit. It is a prospective, randomized, controlled, multicenter study to include 224 patients over 18 months. The impact will be assessed by counting the tablets not taken and by filling an observation booklet with the nurse at home.
Interventions
OTHERnursing visit
nursing visit at patient home
OTHERno nursing visit
the patient take his treatment without nursing visit
Sponsors
Nantes University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 70 and over * Patient initiating an oral anticancer treatment (Chemotherapy, Targeted therapy, 2nd generation hormone therapy type Acetate abiraterone and Enzalutamide) * Patient who received an onco-geriatric assessment * Patient with informed consent signed
Exclusion criteria
* Patient in a medical institution * Patient under exclusive hormone therapy * Patient already eligible for nurse support * Patient not speaking French * Patient under tutelage and guardianship or under safeguard of justice * Patient already included in a research protocol * Patient sharing his or her home with a person receiving nursing care at home more than once a week and for a period longer than 1 month after the patient's inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison, at 3 months after the oncological treatments began, of the observance rate of the anticancer drugs (corresponding to the entire carcinological protocol) with or without passage of a nurse at the patient's home. | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the patient's perception of observance to anticancer therapy | 3 months |
| Comparison of causes of possible premature and definitive cessation of cancer treatments 3 months after the start of treatment and changes in treatment (dose, rhythm of cycles) | 3 months |
| Assessment of patients' satisfaction (of the arm with passage of the nurse) and the professionals | 3 months |
| Determination of the percentage of patients able to be included in the study compared to the number of patients who received an oncogeriatric assessment | 3 months |
Countries
France
Outcome results
None listed